Breast cancer is the most common type of cancer among women. Triple-negative breast cancer (TNBC) is a subtype that is particularly aggressive and has limited treatment options, resulting in poor outcomes. This study focuses on the role of specific miRNAs in the progression of triple-negative breast cancer. Bioinformatics analysis of The Cancer Genome Atlas (TCGA) data identified 195 miRNAs that impact 57 genes associated with resistance to platinum-based therapies. Thus, we selected a subset of miRNAs and determined their expression levels through RT-PCR in triple-negative breast cancer (TNBC) patient samples, both before and after neoadjuvant therapy. Finally, the patients were stratified into a high-risk group and a low-risk group according to the median expression level of each miRNA.
MICRORNA SIGNATURES AS PREDICTIVE TOOLS FOR NEOADJUVANT CHEMOTHERAPY RESPONSES IN TNBC
Domas Štitilis1, 3, Adomas Vasiliauskas3, Linas Kunigėnas1, Monika Drobnienė1, 2, Eglė Strainienė1, 3, Kęstutis Sužiedėlis1, 2
1 National Cancer Institute
2 Life Sciences Center
3 Vilnius Gediminas Technical University